Low-resource countries experience an inequitable burden of cervical cancer. For decades, PATH has been at the forefront of evidence-based strategies from HPV vaccine research and delivery to cervical cancer screening and treatment to ensure we best meet the needs and realities of these countries for the greatest health impact.

What we do

Operational, clinical, and health economics research
We assess and evaluate national HPV vaccine delivery and coverage, conduct studies on the safety and immunogenicity of new HPV vaccines, and estimate the health impact and economic outcomes of different HPV vaccination and cervical cancer screening and treatment strategies and programs.

Technical assistance for vaccine development and introduction
We provide technical support for the development, manufacturing, and registration of new HPV vaccines, and partner with countries for the planning, implementation, and ongoing monitoring of national HPV vaccination programs.

Expert opinion
We convene HPV experts and serve as technical advisors for global and national stakeholders, including the World Health Organization and Gavi, the Vaccine Alliance, on vaccine characteristics and packaging, financing, programs, vaccine schedules and policies.

Cervical cancer screening and treatment
In parallel to primary prevention through HPV vaccination, we advance evidence-based cervical cancer screening and treatment through innovative approaches and technologies such as HPV DNA testing and thermal ablation.

Who we are

Evan Simpson, DrPH
esimpson@path.org
Single-dose Evaluation Consortium

Niranjan Bhat, MD, MHS
nbhat@path.org
Post-licensure Clinical Research

Clint Pecenka, PhD
cpecenka@path.org
Health Economics and Outcomes Research

D. Scott LaMontagne, PhD, MPH
slamontagne@path.org
Country Programs and Implementation

Silvia de Sanjosé, MD, PhD
sdesanjose@path.org
Women’s Cancers

Where we work

PATH has partnered with more than 30 countries to advance research and accelerate access to HPV vaccines
PATH is a global organization that works to accelerate health equity by bringing together public institutions, businesses, social enterprises, and investors to solve the world’s most pressing health challenges. With expertise in science, health, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales solutions—including vaccines, drugs, devices, diagnostics, and innovative approaches to strengthening health systems worldwide. path.org

**PATH will continue to work with our partners including international organizations, governments, foundations, nongovernmental organizations, civil society groups, and other stakeholders to ensure equitable access for HPV vaccine and cervical cancer screening and treatment in the countries that need them the most.**

With our crosscutting expertise in diagnostics, health economics, procurement, clinical research and advocacy and communications, PATH has both the technical knowledge and field experience to assist with assessments, strategic planning, and guideline development as countries respond to the WHO call for cervical cancer elimination.

Learn more about our work to prevent HPV infection at path.org/hpv and subscribe to our newsletter at path.org/hpvflash.

---

**HPV vaccine impact**

**Ethiopia introduces HPV vaccine into their national immunization program**

Ethiopia launched the HPV vaccine into national routine immunization in December 2018 and to date, has vaccinated over 2 million girls. This was achieved through a close partnership between the Federal Ministry of Health; Gavi, the Vaccine Alliance; WHO; United Nations Children's Fund; and PATH. PATH provided technical assistance to plan the demonstration project and submit the Gavi application, and for the planning, logistics, social mobilization, and monitoring and evaluation of the national program.

**Single-dose HPV Vaccine Evaluation Consortium releases second review of evidence**

The Consortium, convened by PATH, includes experts from eight leading research institutions and organizations working together to collate and synthesize existing evidence and evaluate new data on the potential for single-dose HPV vaccination. A single-dose HPV vaccination schedule could offer new options for delivery, alleviate supply constraints, and accelerate access to HPV vaccines, potentially protecting even more girls. Read the report at path.org/singledosehpv.

**CHOISE trial expands HPV vaccine options & new research informs evidence gaps**

In recognition of the slower uptake of HPV vaccines in low- and-middle income countries, PATH is conducting the CHOISE trial - Comparing HPV vaccine Options: Immunogenicity and Safety Evaluation, a randomized controlled trial. The trial will evaluate Innovax’s new bivalent HPV vaccine comparing multiple two-dose regimens against the quadrivalent HPV vaccine. In parallel, we will conduct a set of health economic evaluations of HPV vaccine implementation to inform evidence gaps at the global and country level.

---

**What’s next**

PATH will continue to work with our partners including international organizations, governments, foundations, nongovernmental organizations, civil society groups, and other stakeholders to ensure equitable access for HPV vaccine and cervical cancer screening and treatment in the countries that need them the most.

PATH is a global organization that works to accelerate health equity by bringing together public institutions, businesses, social enterprises, and investors to solve the world’s most pressing health challenges. With expertise in science, health, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales solutions—including vaccines, drugs, devices, diagnostics, and innovative approaches to strengthening health systems worldwide. path.org

**Date Published:** June 2020